Skip to main content
SpringerLink
Log in

Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies

  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Objective

To evaluate the relationship of ovarian activity on Ca125 production, we studied whether Ca125 production varies during the menstrual cycle both in normal ovulatory women and in women whose ovarian factors are significantly stimulated by multiple follicular development (MFD). Furthermore, since the first 12 weeks of pregnancy is characterized by the enhancement of corpus luteum function mainly in MFD-induced pregnancies, Ca125 levels were also evaluated in the first quarter of pregnancy both in spontaneous and in MFD-induced pregnancies.

Subjects

Subjects were normal ovulatory women in the late follicular phase (FP) (N =20) and in the luteal phase (LP) (N =20), 32 infertile women submitted to MFD with pure FSH, and 40 pregnant women in which pregnancy occurred spontaneously (N =20) or after induction of MFD (N =20).

Results and Conclusions

In regularly cycling women plasma Ca125 levels were constant during the menstrual cycle. In contrast, in stimulated cycles Ca125 levels were significantly higher (P < 0.0008) in the LP than in the FP. In addition, in these subjects Ca125 levels in the LP were significantly correlated (P < 0.0001, r = 0.686) with E2 plasma levels. These data strongly suggest that an increase in corpus luteum function could be involved in Ca125 production. Since granulosa cells have not been demonstrated to produce Ca125, it can be hypothesized that endometrial or peritoneal cells submitted to exaggerated stimulation by ovarian activity are the source of increased Ca125 secretion. In agreement with this hypothesis, Ca125 levels were significantly higher in the first weeks of spontaneous pregnancies than in the luteal phase and they were also higher in MFD-induced pregnancies than in spontaneous pregnancies (P < 0.001).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981 ;68:1331–1337

    Google Scholar 

  2. Bast RCjr, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF: Monitoring human ovarian carcinoma with a combination of Ca125, CA 19-9 and carcinoembryonic antigen. Am J Obstet Gynecol 1984;149:553–559

    Google Scholar 

  3. Duk JM, Aalders JG, Fleuren GI, de Brujn HWA: Ca-125 a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:1097–1102

    Google Scholar 

  4. Jacobs I, Bast RC: The Ca125 tumor-associated antigen: A review of the literature. Hum Reprod 1989;4:1–12

    Google Scholar 

  5. Barbieri RL, Niloff JM, Bast RCjr, Schaezl E, Kistner RW, Knapp RC: Elevated serum concentrations of Ca125 in patients with advanced endometriosis. Fertil Steril 1986;45:630–634

    Google Scholar 

  6. Bischof P, Galfetti MA, Seydoux J, von Hospenthal JU, Campana A: Peripheral Ca125 levels in patients with uterine fibroids. Hum Reprod 1992;7:35–38

    Google Scholar 

  7. Niloff JM, Knapp RC, Schaetzl E, Reynolds V, Bast RC Jr: Ca125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984;64:703–705

    Google Scholar 

  8. Halila H, Stenman UH, Seppala M: Ovarian cancer antigen Ca125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986;57:1327–1330

    Google Scholar 

  9. Dietel M, Harps H, Klapdor R, Muller-Hagen S, Sieck M, Hoffmann L: Antigen detection by the monoclonal antibodies Ca19-9 and Ca125 in normal and tumor tissue and patients sera. J Cancer Res Clin Oncol 1986;11:257–260

    Google Scholar 

  10. Grover S, Quinn MA, Weideman P, Koh H: Factors influencing serum Ca125 levels in normal women. Obstet Gynecol 1992;79:511–514

    Google Scholar 

  11. Jacobs IJ, Fay TN, Stabile I, Bridges J, Oram DHO, Grudzinkas JG: The distribution of Ca125 in the reproductive tract of pregnant and non-pregnant women. Br J Obstet Gynecol 1988;95:1190–1194

    Google Scholar 

  12. Brumsted JR, McBean JH, Deaton JL, Gibson M: Ca125 secretion by luteal endometrium in vitro. Hum Reprod 1990;5:682–684

    Google Scholar 

  13. Abaé M, Gibson M, Chapitis J, Riddick DH, Brumsted JR: Ca125 levels in human uterine fluid. Fertil Steril 1992;57:531–534

    Google Scholar 

  14. Henk WA, de Bruin A, van Beek Calkoen-Carpay T, Ager S, Duk JM, Aalders JG, Fleuren GJ: The tumor marker Ca125 is a common constituent of normal cervical mucus. Am J Obstet Gynecol 1986;154:1088–1091

    Google Scholar 

  15. Williams RS, Venkateswara Rao CH, Yussman MA: Interference of the measurement of Ca125 in peritoneal fluid. Fertil Steril 1988;49:547–550

    Google Scholar 

  16. Zeimet AG, Muller-Holtzner E, Mart C, Daxenbichler G, Dapunt O: Tumor marker Ca-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril 1993;59:1028–1035

    Google Scholar 

  17. Jager W, Meier C, Wildt L, Sauerbrei W, Lang N: Ca125 serum concentrations during the menstrual cycle. Fertil Steril 1988;50:223–227

    Google Scholar 

  18. Ozasa H, Noda Y, Mori T: Progesterone increases serum Ca-125 in endometriosis. Fertil Steril 1987;47:699–701

    Google Scholar 

  19. Zweers A, De Boever J, Serreyn R, Vandekerckhove D: Correlation between peripheral Ca125 levels and ovarian activity. Fertil Steril 1990;54:409–414

    Google Scholar 

  20. Jager W, Diedrich K, Wildt L: Elevated levels of Ca125 in serum of patients suffering from ovarian hyperstimulation syndrome. Fertil Steril 1987;48:675–680

    Google Scholar 

  21. Pittaway DE, Fayez JA: Serum Ca125 antigen levels increase during menses. Am J Obstet Gynecol 1987;156:76–77

    Google Scholar 

  22. Lehtovirta P, Apter D, Stenman UH: Serum Ca125 levels during the menstrual cycle. Br J Obstet Gynecol 1990;97:930–933

    Google Scholar 

  23. Grover S, Koh H, Weidmann P, Quinn MA: The effect of the menstrual cycle on serum Ca125 levels: A population study. Am J Obstet Gynecol 1992;167:1379–1381

    Google Scholar 

  24. Lanzone A, Fulghesu AM, Guida C, Muscatello R, Caruso A, Mancuso S: Serum Ca-125 levels do not depend on ovarian steroidogenesis. Fertil Steril 1990;54:415–418

    Google Scholar 

  25. Zweers A, De Boever J, Serreyn R, Vandekerckove D: Correlation between peripheral Ca 125 levels and ovarian activity. Fertil Steril 1990;54:409–414

    Google Scholar 

  26. Fuith LC, Muller-Holzner E, Marth C, Zeimet AG, Perkmann E, Daxenbichler G: Distribution of Ca125 in placental tissues. Int J Biol Markers 1989;4:78–80

    Google Scholar 

  27. Seki K, Kikuchi Y, Uesato T, Kato K: Increased serum Ca125 levels during the first trimester of pregnancy. Acta Obstet Gynecol Scand 1986;65:583–585

    Google Scholar 

  28. Bischof P: What do we know about the origin of Ca 125? Eur J Obstet Gynecol Reprod Biol 1993;49:93–98

    Google Scholar 

  29. Holt JA, Wagener SE, Lee EY, Hubbay MM, Hamilton TH: Serum Ca 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen or progestin. Gynecol Oncol 1987;27:282–293

    Google Scholar 

  30. Marana R, Muzii L, Muscatello P, Lanzone A, Caruso A, Dell'Acqua S, Mancuso S: Gonadotrophin releasing hormone agonist (buserelin) in the treatment of endometriosis: Changes in the extent of the disease and in Ca125 serum levels after 6-month therapy. Br J Obstet Gynaecol 1990;97: 1016–1019

    Google Scholar 

  31. Franssen AMHW, van der Heijden PFM, Thomas CMG, Doesburg WH, Willemsen WNP, Rolland R: On the origin and significance of serum Ca-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. Fertil Steril 1992;57:974–979

    Google Scholar 

  32. Van Der Zee AGJ, Duk JM, Aalders JG, Boontje ABH, Ten Hoor KA, De Bruijn HWA: The effect of abdominal surgery on the serum concentration of the tumour-associated antigen Ca125. Br J Obstet Gynaecol 1990;97:934–938

    Google Scholar 

  33. Jones EE: Gametogenesis, fertilization and implantation.In Medicine of the Fetus and Mother, EA Reece, JC Hobbins, MJ Mahoney, RH Pettie (eds). Philadelphia, Lippincott, 1992, pp 7–24

    Google Scholar 

  34. Csapo AI, Pulkkinen MO, Wiest WG: Effects of lutecoectomy and progesterone replacement in early pregnant patients. Am J Obstet Gynecol 1973;115:759–762

    Google Scholar 

  35. Melis GB, Paoletti AM, Strigini F, Menchini-Fabris F, Canale D, Fioretti P: Pharmacologic induction of multiple follicular development improves the success rate of artificial insemination with husband's semen in couples with male-related or unexplained infertility. Fertil Steril 1987;47:441–445

    Google Scholar 

  36. Mascarenhas L, Khastgir G, Davies WAR and Lee S: Superovulation and timed intercourse: Can it provide a reasonable alternative for those unable to afford assisted conception? Hum Reprod 1994;9:67–70

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Ginecologia Ostetricia e Fisiopatologia della Riproduzione Umana, Ospedale San Giovanni di Dio, Via Ospedale 46, 09124, Cagliari, Italy

    Anna Maria Paoletti, Gian Giacomo Serra, Valerio Mais, Silvia Ajossa, Stefano Guerriero, Marisa Orrú & Gian Benedetto Melis

Authors
  1. Anna Maria Paoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gian Giacomo Serra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valerio Mais
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Ajossa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefano Guerriero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marisa Orrú
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gian Benedetto Melis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paoletti, A.M., Serra, G.G., Mais, V. et al. Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies. J Assist Reprod Genet 12, 263–268 (1995). https://doi.org/10.1007/BF02212929

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02212929

Key words

Search

Navigation